FDA accelerates review of Novartis' sickle cell drug

The FDA has accelerated its review of Novartis’ sickle cell drug crizanlizumab after the company filed phase 2 results showing its effectiveness as a treatment for life threatening and pain

Gilead invests $5.1bn in Belgian biotech Galapagos

Belgian biotech Galapagos has signed a shiny new deal with Gilead to develop inflammatory disease and rheumatoid arthritis drugs, where the big US pharma will pay $3.95 billion up front and

Novartis trims again with $390m drugs sale to Recordati

Novartis and Amgen axe BACE drug for Alzheimer's

Another Alzheimer’s disease drug has been axed after Novartis, Amgen and the Banner Alzheimer’s Institute decided to end two pivotal studies involving a medicine targeting BACE.

FDA fast tracks Prevail's Parkinson's gene therapy

The FDA has fast tracked a gene therapy for a certain form of Parkinson’s Disease from US biotech Prevail Therapeutics.

ViiV hails data showing switch from Truvada to two-drug HIV ...

ViiV is continuing its assault on arch-rival Gilead in HIV, with phase 3 results aimed at giving doctors confidence that patients can switch from rival triple therapies to its new two-drug